How to spot a stem cell scam

Claims to cure many unrelated conditions are a major warning sign. The EMA and Heads of Medicines Agencies warn about products promoted with benefits that are not supported by medical literature. Testimonials, star ratings and selected success stories are not clinical evidence. Ask for a protocol, prespecified outcomes, complete follow-up and peer-reviewed results for the exact product and indication. A provider that will not give its exact legal name, facility address, responsible clinician and authorising authority cannot be independently checked. Company registration alone is not medical authorisation. Vague descriptions such as regenerative cells or secretome are insufficient. Obtain cell or tissue source, processing, manufacturer, dose, route, batch or traceability information and intended indication. Calling a product experimental does not create a lawful route. For an EU ATMP, verify marketing authorisation, an authorised clinical trial or a specific national hospital exemption with the competent authority. Claims that a clinic itself is FDA-approved or EMA-approved are misleading. Regulators authorise defined products, trials, manufacturing activities or uses; the scope must match the offer. Pressure to pay immediately, secrecy about contracts or a discount tied to same-day consent undermines informed decision-making. Ask for the full documents before transferring money. Consent that omits investigational status, uncertainties, alternatives, material risks, data use, costs and complication responsibility is inadequate. Consent is a process with a qualified clinician, not a signature collected by sales staff. Check each clinician in the relevant professional register and confirm who is clinically responsible. Academic titles, conference photographs and publication lists do not replace current registration and scope of practice. A headline price without included and excluded items can hide substantial exposure. Require a dated quote, cancellation terms and a clear statement of who pays for additional care or extended stay. Follow-up must identify outcomes, contacts and escalation. A provider that cannot issue a discharge record or coordinate with your usual clinician leaves a predictable continuity-of-care gap. You have rights over personal data and cross-border records, but do not rely on a fabricated fixed-copy fee. European Commission guidance says the first GDPR copy is generally free, with limited exceptions for further or excessive requests. Evidence from another disease, product or route cannot validate the proposed use. A trial citation must match the sponsor, intervention, site, status and population in the official registry. Perfectly uniform online reviews may justify further checking, but reviews alone cannot prove fraud or quality. Give more weight to official registers, original documents and independent clinical evidence. Claims that regulators suppress a hidden cure are not a substitute for data. Regulation does not guarantee benefit, but avoiding identifiable oversight removes safeguards rather than proving innovation. Unsolicited contact, repeated sales pressure and communication only through disappearing messages are risk signals. Preserve correspondence and insist on formal clinical channels and contracts. Stop when verification fails. Contact the national competent authority, cross-border healthcare National Contact Point or an independent specialist before proceeding; do not ask the seller to be the sole judge of its own legality.

Sources & further reading

• Stem-cell trials registry (ClinicalTrials.gov) ↗
• Peer-reviewed research (PubMed) ↗
• ISSCR — patient resources ↗
• FDA — consumer guidance ↗
• EMA — ATMP framework ↗

Educational guide; most uses are investigational. Verify the exact product, indication and provider with current regulator records and an independent qualified physician.